Arcus Biosciences, Inc.

Arcus Biosciences is a clinical-stage biopharmaceutical company whose core business model involves animal testing as a required step in the development of its oncology drug candidates. The company’s pipeline of investigational therapies, which target mechanisms like TIGIT and CD73, relies on preclinical animal studies to assess efficacy and safety before advancing to human trials. This exploitation of animals for medical research and analysis is a fundamental component of its business, as documented by Cruelty Free Investors.

The company’s contractual language further institutionalizes this exploitation. Its collaboration and license agreements explicitly define “Veterinary Use” as the “Exploitation” of a molecule for the prevention or treatment of medical conditions in animals, indicating a formalized pathway for extending its research into veterinary applications. While Arcus operates in a highly regulated industry where animal testing is often mandated for regulatory approval, its business remains fundamentally dependent on the commercial exploitation of animals for preclinical development.